Suppr超能文献

鉴定靶向主要蛋白酶(M)和组织蛋白酶L的双重抑制剂作为潜在的抗SARS-CoV-2药物

Identification of Dual Inhibitors Targeting Main Protease (M) and Cathepsin L as Potential Anti-SARS-CoV-2 Agents.

作者信息

Previti Santo, Ettari Roberta, Calcaterra Elsa, Roggia Michele, Natale Benito, Weldert Annabelle C, Müller-Ruttloff Christin, Salisch Florian, Irto Anna, Cigala Rosalia Maria, Ziebuhr John, Schirmeister Tanja, Cosconati Sandro, Zappalà Maria

机构信息

Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Stagno d'Alcontres 31, 98166 Messina, Italy.

DiSTABiF, University of Campania Luigi Vanvitelli, Via Vivaldi 43, 81100 Caserta, Italy.

出版信息

ACS Med Chem Lett. 2024 Mar 1;15(5):602-609. doi: 10.1021/acsmedchemlett.3c00562. eCollection 2024 May 9.

Abstract

In this structure-activity relationship (SAR) study, we report the development of dual inhibitors with antiviral properties targeting the SARS-CoV-2 main protease (M) and human cathepsin L (hCatL). The novel molecules differ in the aliphatic amino acids at the P2 site and the fluorine position on the phenyl ring at the P3 site. The identified dual inhibitors showed values within 1.61 and 10.72 μM against SARS-CoV-2 M; meanwhile, values ranging from 0.004 to 0.701 μM toward hCatL were observed. A great interdependency between the nature of the side chain at the P2 site and the position of the fluorine atom was found. Three dual-targeting inhibitors exhibited antiviral activity in the low micromolar range with CC values >100 μM. Docking simulations were executed to gain a deeper understanding of the SAR profile. The findings herein collected should be taken into consideration for the future development of dual SARS-CoV-2 M/hCatL inhibitors.

摘要

在本构效关系(SAR)研究中,我们报告了针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)主要蛋白酶(M)和人组织蛋白酶L(hCatL)开发具有抗病毒特性的双重抑制剂。这些新型分子在P2位点的脂肪族氨基酸和P3位点苯环上的氟位置有所不同。所鉴定的双重抑制剂对SARS-CoV-2 M的IC₅₀值在1.61至10.72 μM范围内;同时,观察到对hCatL的IC₅₀值在0.004至0.701 μM之间。发现P2位点侧链的性质与氟原子的位置之间存在很大的相互依赖性。三种双靶点抑制剂在低微摩尔范围内表现出抗病毒活性,其CC₅₀值>100 μM。进行了对接模拟以更深入地了解构效关系概况。本文收集的研究结果应在双重SARS-CoV-2 M/hCatL抑制剂的未来开发中予以考虑。

相似文献

1
Identification of Dual Inhibitors Targeting Main Protease (M) and Cathepsin L as Potential Anti-SARS-CoV-2 Agents.
ACS Med Chem Lett. 2024 Mar 1;15(5):602-609. doi: 10.1021/acsmedchemlett.3c00562. eCollection 2024 May 9.
2
Dual Inhibitors of SARS-CoV-2 3CL Protease and Human Cathepsin L Containing Glutamine Isosteres Are Anti-CoV-2 Agents.
J Am Chem Soc. 2025 Jan 15;147(2):1631-1648. doi: 10.1021/jacs.4c11620. Epub 2025 Jan 2.
3
Structure-based lead optimization of peptide-based vinyl methyl ketones as SARS-CoV-2 main protease inhibitors.
Eur J Med Chem. 2023 Feb 5;247:115021. doi: 10.1016/j.ejmech.2022.115021. Epub 2022 Dec 15.
4
MPI8 is Potent against SARS-CoV-2 by Inhibiting Dually and Selectively the SARS-CoV-2 Main Protease and the Host Cathepsin L.
ChemMedChem. 2022 Jan 5;17(1):e202100456. doi: 10.1002/cmdc.202100456. Epub 2021 Jul 29.
5
A multi-pronged evaluation of aldehyde-based tripeptidyl main protease inhibitors as SARS-CoV-2 antivirals.
Eur J Med Chem. 2022 Oct 5;240:114570. doi: 10.1016/j.ejmech.2022.114570. Epub 2022 Jun 27.
6
A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals.
Eur J Med Chem. 2022 Oct 5;240:114596. doi: 10.1016/j.ejmech.2022.114596. Epub 2022 Jul 8.
9
Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease.
Antiviral Res. 2011 Nov;92(2):204-12. doi: 10.1016/j.antiviral.2011.08.001. Epub 2011 Aug 11.
10
Development of acylhydrazone linked thiazoles as non-covalent dual inhibitors of SARS-CoV-2 proteases.
Eur J Med Chem. 2025 Jun 5;290:117509. doi: 10.1016/j.ejmech.2025.117509. Epub 2025 Mar 13.

本文引用的文献

2
Accelerating antiviral drug discovery: lessons from COVID-19.
Nat Rev Drug Discov. 2023 Jul;22(7):585-603. doi: 10.1038/s41573-023-00692-8. Epub 2023 May 12.
3
Vaccines and therapeutics for immunocompromised patients with COVID-19.
EClinicalMedicine. 2023 May;59:101965. doi: 10.1016/j.eclinm.2023.101965. Epub 2023 Apr 12.
6
Structure-based lead optimization of peptide-based vinyl methyl ketones as SARS-CoV-2 main protease inhibitors.
Eur J Med Chem. 2023 Feb 5;247:115021. doi: 10.1016/j.ejmech.2022.115021. Epub 2022 Dec 15.
7
Structure determinants defining the specificity of papain-like cysteine proteases.
Comput Struct Biotechnol J. 2022 Nov 24;20:6552-6569. doi: 10.1016/j.csbj.2022.11.040. eCollection 2022.
8
Dual Inhibitors of Main Protease (M) and Cathepsin L as Potent Antivirals against SARS-CoV2.
J Am Chem Soc. 2022 Nov 23;144(46):21035-21045. doi: 10.1021/jacs.2c04626. Epub 2022 Nov 10.
9
Easy access to α-ketoamides as SARS-CoV-2 and MERS M inhibitors via the PADAM oxidation route.
Eur J Med Chem. 2022 Dec 15;244:114853. doi: 10.1016/j.ejmech.2022.114853. Epub 2022 Oct 17.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验